Analysts expect Endologix, Inc. (NASDAQ:ELGX) to announce $34.18 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Endologix’s earnings, with estimates ranging from $32.40 million to $35.00 million. Endologix reported sales of $42.28 million during the same quarter last year, which indicates a negative year over year growth rate of 19.2%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, May 1st.
According to Zacks, analysts expect that Endologix will report full-year sales of $141.31 million for the current financial year, with estimates ranging from $140.50 million to $142.15 million. For the next fiscal year, analysts forecast that the business will report sales of $151.11 million, with estimates ranging from $148.03 million to $153.30 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Endologix.
Several research firms have weighed in on ELGX. ValuEngine raised shares of Endologix from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research downgraded shares of Endologix from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 21st. Finally, BTIG Research reissued a “buy” rating on shares of Endologix in a research report on Tuesday, February 26th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $29.17.
Shares of Endologix stock traded down $0.02 on Tuesday, reaching $6.61. The stock had a trading volume of 109,448 shares, compared to its average volume of 218,137. The company has a quick ratio of 0.96, a current ratio of 1.55 and a debt-to-equity ratio of 4.38. Endologix has a 1 year low of $5.20 and a 1 year high of $67.20. The company has a market cap of $68.38 million, a P/E ratio of -0.92 and a beta of 0.54.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
See Also: How a Back-End Load Mutual Fund Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.